Next Article in Journal
Amyloid-Beta Peptides and Activated Astroglia Impairs Proliferation of Nerve Growth Factor Releasing Cells In Vitro: Implication for Encapsulated Cell Biodelivery-Mediated AD Therapy
Next Article in Special Issue
Modulation of FLT3-ITD Localization and Targeting of Distinct Downstream Signaling Pathways as Potential Strategies to Overcome FLT3-Inhibitor Resistance
Previous Article in Journal
Adenosine Receptor Antagonists to Combat Cancer and to Boost Anti-Cancer Chemotherapy and Immunotherapy
Previous Article in Special Issue
Distinct Clinical Impact and Biological Function of Angiopoietin and Angiopoietin-like Proteins in Human Breast Cancer
Review

A Role for the Bone Marrow Microenvironment in Drug Resistance of Acute Myeloid Leukemia

1
Department of Immunology, Razi Vaccine and Sera Research Institute, Karaj, Iran
2
Department of Pharmacology, Karaj Branch, Islamic Azad University, Karaj, Iran
3
Department of Hematology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran
4
Centre for Haematology, Hammersmith Hospital, Imperial College London, London W12 0HS, UK
5
Center of Emphasis in Cancer, Department of Molecular and Translational Medicine, Texas Tech University Health Sciences Center at El Paso, El Paso, TX 79905, USA
*
Author to whom correspondence should be addressed.
These authors contributed equally to this work.
Academic Editor: Frank Schnütgen
Cells 2021, 10(11), 2833; https://doi.org/10.3390/cells10112833
Received: 22 September 2021 / Revised: 13 October 2021 / Accepted: 14 October 2021 / Published: 21 October 2021
(This article belongs to the Special Issue Emerging Cancer Target Genes)
Acute myeloid leukemia (AML) is a heterogeneous disease with a poor prognosis and remarkable resistance to chemotherapeutic agents. Understanding resistance mechanisms against currently available drugs helps to recognize the therapeutic obstacles. Various mechanisms of resistance to chemotherapy or targeted inhibitors have been described for AML cells, including a role for the bone marrow niche in both the initiation and persistence of the disease, and in drug resistance of the leukemic stem cell (LSC) population. The BM niche supports LSC survival through direct and indirect interactions among the stromal cells, hematopoietic stem/progenitor cells, and leukemic cells. Additionally, the BM niche mediates changes in metabolic and signal pathway activation due to the acquisition of new mutations or selection and expansion of a minor clone. This review briefly discusses the role of the BM microenvironment and metabolic pathways in resistance to therapy, as discovered through AML clinical studies or cell line and animal models. View Full-Text
Keywords: drug resistance; acute myeloid leukemia; bone marrow microenvironment; leukemic stem cell drug resistance; acute myeloid leukemia; bone marrow microenvironment; leukemic stem cell
Show Figures

Figure 1

MDPI and ACS Style

Bolandi, S.M.; Pakjoo, M.; Beigi, P.; Kiani, M.; Allahgholipour, A.; Goudarzi, N.; Khorashad, J.S.; Eiring, A.M. A Role for the Bone Marrow Microenvironment in Drug Resistance of Acute Myeloid Leukemia. Cells 2021, 10, 2833. https://doi.org/10.3390/cells10112833

AMA Style

Bolandi SM, Pakjoo M, Beigi P, Kiani M, Allahgholipour A, Goudarzi N, Khorashad JS, Eiring AM. A Role for the Bone Marrow Microenvironment in Drug Resistance of Acute Myeloid Leukemia. Cells. 2021; 10(11):2833. https://doi.org/10.3390/cells10112833

Chicago/Turabian Style

Bolandi, Seyed M., Mahdi Pakjoo, Peyman Beigi, Mohammad Kiani, Ali Allahgholipour, Negar Goudarzi, Jamshid S. Khorashad, and Anna M. Eiring 2021. "A Role for the Bone Marrow Microenvironment in Drug Resistance of Acute Myeloid Leukemia" Cells 10, no. 11: 2833. https://doi.org/10.3390/cells10112833

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop